Lost in Translation: A Disconnect Between the Science and Medicare Coverage Criteria for Continuous Subcutaneous Insulin Infusion

Numerous studies have demonstrated the clinical value and safety of insulin pump therapy in type 1 diabetes and type 2 diabetes populations. However, the eligibility criteria for insulin pump coverage required by the Centers for Medicare & Medicaid Services (CMS) discount conclusive evidence that supports insulin pump use in diabetes populations that are currently deemed ineligible. This article discusses the limitations and inconsistencies of the insulin pump eligibility criteria relative to current scientific evidence and proposes workable solutions to address this issue and improve the safety and care of all individuals with diabetes.

[1]  I. Hirsch,et al.  The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2021, Diabetologia.

[2]  B. Kovatchev,et al.  One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology , 2021, Diabetes technology & therapeutics.

[3]  Lauren M. Huyett,et al.  Improved Glycemic Control in 3,592 Adults with Type 2 Diabetes Mellitus Initiating a Tubeless Insulin Management System. , 2021, Diabetes research and clinical practice.

[4]  D. Mohr,et al.  Association between hemoglobin A1c variability and hypoglycemia-related hospitalizations in veterans with diabetes mellitus , 2021, BMJ Open Diabetes Research & Care.

[5]  Lauren M. Huyett,et al.  First Outpatient Evaluation of a Tubeless Automated Insulin Delivery System with Customizable Glucose Targets in Children and Adults with Type 1 Diabetes , 2020, Diabetes technology & therapeutics.

[6]  Yohannes Tsegyie Wondmkun.  Obesity, Insulin Resistance, and Type 2 Diabetes: Associations and Therapeutic Implications , 2020, Diabetes, metabolic syndrome and obesity : targets and therapy.

[7]  Maher R. Khdour,et al.  Treatment Satisfaction and Quality of Life among Type 2 Diabetes Patients: A Cross-Sectional Study in West Bank, Palestine , 2020, Journal of diabetes research.

[8]  Guillermo Guzmán,et al.  Glycemic Control and Hypoglycemia in Patients Treated with Insulin Pump Therapy: An Observational Study , 2020, Journal of diabetes research.

[9]  D. Rodbard,et al.  Glucose Variability and Time in Range in Type 2 Diabetes Treated with U-500R by Pump or Injection: CGM findings from the VIVID study. , 2020, Diabetes technology & therapeutics.

[10]  R. Vigersky,et al.  97-LB: Safety and Glycemic Outcomes of the MiniMed Advanced Hybrid Closed-Loop (AHCL) System in Subjects with T1D , 2020 .

[11]  Elham Monaghesh,et al.  The role of telehealth during COVID-19 outbreak: a systematic review based on current evidence , 2020, BMC Public Health.

[12]  N. Argento,et al.  Impact of Medicare Continuous Subcutaneous Insulin Infusion Policies in Patients With Type 1 Diabetes , 2020, Journal of diabetes science and technology.

[13]  M. B. Christensen,et al.  Glycaemic variability and hypoglycaemia are associated with C-peptide levels in insulin-treated type 2 diabetes. , 2020, Diabetes & metabolism.

[14]  K. Khunti,et al.  Adherence to type 2 diabetes management , 2019 .

[15]  E. Gregg,et al.  Diabetes Prevalence and Incidence Among Medicare Beneficiaries — United States, 2001–2015 , 2019, MMWR. Morbidity and mortality weekly report.

[16]  Eyal Dassau,et al.  Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes. , 2019, The New England journal of medicine.

[17]  G. Grunberger,et al.  Glycemic Outcomes in Adults With T1D Are Impacted More by Continuous Glucose Monitoring Than by Insulin Delivery Method: 3 Years of Follow-Up From the COMISAIR Study , 2019, Diabetes Care.

[18]  S. Manson,et al.  Understanding the Economic Costs of Diabetes and Prediabetes and What We May Learn About Reducing the Health and Economic Burden of These Conditions , 2019, Diabetes Care.

[19]  P. Hollander,et al.  Risk of clinically relevant hypoglycaemia in patients with type 2 diabetes self‐titrating insulin glargine U‐100 , 2019, Diabetes, obesity & metabolism.

[20]  W. Lane,et al.  Comment on Feig et al. Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial. Diabetes Care 2018;41:2471–2479 , 2019, Diabetes Care.

[21]  Boris Kovatchev,et al.  Glycemic Variability: Risk Factors, Assessment, and Control , 2019, Journal of diabetes science and technology.

[22]  A. Alqarni,et al.  Adherence to diabetes medication among diabetic patients in the Bisha governorate of Saudi Arabia – a cross-sectional survey , 2018, Patient preference and adherence.

[23]  G. Tomlinson,et al.  Pumps or Multiple Daily Injections in Pregnancy Involving Type 1 Diabetes: A Prespecified Analysis of the CONCEPTT Randomized Trial , 2018, Diabetes Care.

[24]  W. Kernan,et al.  Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2018, Diabetologia.

[25]  Zixiang Wu,et al.  Evaluation of the clinical outcomes of telehealth for managing diabetes , 2018, Medicine.

[26]  Priyamvada Singh,et al.  Insulin Pump in Difficult to Control Type 2 Diabetes: A Single Center, Five Years' Experience , 2018, Cureus.

[27]  Gregory P. Forlenza,et al.  Predictive Low-Glucose Suspend Reduces Hypoglycemia in Adults, Adolescents, and Children With Type 1 Diabetes in an At-Home Randomized Crossover Study: Results of the PROLOG Trial , 2018, Diabetes Care.

[28]  G. Grunberger,et al.  C-PEPTIDE AND BETA-CELL AUTOANTIBODY TESTING PRIOR TO INITIATING CONTINUOUS SUBCUTANEOUS INSULIN INFUSION PUMP THERAPY DID NOT IMPROVE UTILIZATION OR MEDICAL COSTS AMONG OLDER ADULTS WITH DIABETES MELLITUS. , 2018, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[29]  J. Zgibor,et al.  Examining the Association between Treatment Satisfaction and Medication Adherence among Patients with Poorly Controlled Type 2 Diabetes , 2018, Diabetes.

[30]  H. Khan,et al.  Biomarker potential of C-peptide for screening of insulin resistance in diabetic and non-diabetic individuals , 2018, Saudi journal of biological sciences.

[31]  R. Vigersky,et al.  IMPROVED HBA1C, TOTAL DAILY INSULIN DOSE, AND TREATMENT SATISFACTION WITH INSULIN PUMP THERAPY COMPARED TO MULTIPLE DAILY INSULIN INJECTIONS IN PATIENTS WITH TYPE 2 DIABETES IRRESPECTIVE OF BASELINE C-PEPTIDE LEVELS. , 2018, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[32]  L. Lim,et al.  Beyond HbA1c: Comparing Glycemic Variability and Glycemic Indices in Predicting Hypoglycemia in Type 1 and Type 2 Diabetes. , 2018, Diabetes technology & therapeutics.

[33]  Ping Zhang,et al.  Economic Costs of Diabetes in the U.S. in 2017 , 2018, Diabetes Care.

[34]  Fernando Fernandez-Llimos,et al.  Economic impact of medication non-adherence by disease groups: a systematic review , 2018, BMJ Open.

[35]  Scott W. Lee,et al.  Complex Assessment of Metabolic Effectiveness of Insulin Pump Therapy in Patients with Type 2 Diabetes Beyond HbA1c Reduction , 2017, Diabetes technology & therapeutics.

[36]  Michelle Perkins,et al.  Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial , 2017, The Lancet.

[37]  H. Mehta,et al.  Direct Medical Costs Of Hypoglycemia Hospitalizations In The United States , 2017 .

[38]  J. McGill,et al.  Continuous Glucose Monitoring Versus Usual Care in Patients With Type 2 Diabetes Receiving Multiple Daily Insulin Injections: A Randomized Trial. , 2017, Annals of internal medicine.

[39]  Bruce W Bode,et al.  Effect of initiating use of an insulin pump in adults with type 1 diabetes using multiple daily insulin injections and continuous glucose monitoring (DIAMOND): a multicentre, randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[40]  B. Perkins,et al.  Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials. , 2017, The lancet. Diabetes & endocrinology.

[41]  C. Sainsbury,et al.  A Practical Review of C-Peptide Testing in Diabetes , 2017, Diabetes Therapy.

[42]  K. Ruedy,et al.  Continuous Glucose Monitoring in Older Adults With Type 1 and Type 2 Diabetes Using Multiple Daily Injections of Insulin: Results From the DIAMOND Trial , 2017, Journal of diabetes science and technology.

[43]  N. Hermanns,et al.  Use of Flash Glucose-Sensing Technology for 12 months as a Replacement for Blood Glucose Monitoring in Insulin-treated Type 2 Diabetes , 2017, Diabetes Therapy.

[44]  Howard Wolpert,et al.  Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomized Clinical Trial , 2017, JAMA.

[45]  H. Zisser,et al.  Efficacy of a Tubeless Patch Pump in Patients With Type 2 Diabetes Previously Treated With Multiple Daily Injections , 2017, Journal of diabetes science and technology.

[46]  Gerry Rayman,et al.  Flash Glucose-Sensing Technology as a Replacement for Blood Glucose Monitoring for the Management of Insulin-Treated Type 2 Diabetes: a Multicenter, Open-Label Randomized Controlled Trial , 2016, Diabetes Therapy.

[47]  P. Geelhoed-Duijvestijn,et al.  Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial , 2016, The Lancet.

[48]  K. Boye,et al.  Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database , 2016, Patient preference and adherence.

[49]  W. Polonsky,et al.  Poor medication adherence in type 2 diabetes: recognizing the scope of the problem and its key contributors , 2016, Patient preference and adherence.

[50]  R. Aronson,et al.  Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12‐month data from the OpT2mise randomized trial , 2016, Diabetes, obesity & metabolism.

[51]  D. Marrero,et al.  Impact of CMS Competitive Bidding Program on Medicare Beneficiary Safety and Access to Diabetes Testing Supplies: A Retrospective, Longitudinal Analysis , 2016, Diabetes Care.

[52]  G. Petrovski,et al.  The Impact of Insulin Pump Therapy on Glycemic Profiles in Patients with Type 2 Diabetes: Data from the OpT2mise Study , 2016, Diabetes technology & therapeutics.

[53]  R. Beck,et al.  Risk Factors Associated With Severe Hypoglycemia in Older Adults With Type 1 Diabetes , 2015, Diabetes Care.

[54]  Tracy L. Morris,et al.  Use of V-Go® Insulin Delivery Device in Patients with Sub-optimally Controlled Diabetes Mellitus: A Retrospective Analysis from a Large Specialized Diabetes System , 2015, Diabetes Therapy.

[55]  G. Dogbey,et al.  Hypoglycemia in Type 2 Diabetes - More Common Than You Think , 2015, Journal of diabetes science and technology.

[56]  B. Charbonnel,et al.  Frequency and predictors of confirmed hypoglycaemia in type 1 and insulin-treated type 2 diabetes mellitus patients in a real-life setting: results from the DIALOG study. , 2015, Diabetes & metabolism.

[57]  A. Nicolucci,et al.  Incidence and risk factors for severe and symptomatic hypoglycemia in type 1 diabetes. Results of the HYPOS-1 study , 2015, Acta Diabetologica.

[58]  A. León,et al.  C-peptide as a risk factor of coronary artery disease in the general population , 2015, Diabetes & vascular disease research.

[59]  Chuan-Fen Liu,et al.  Factors affecting medication adherence: patient perspectives from five veterans affairs facilities , 2014, BMC Health Services Research.

[60]  R. Aronson,et al.  Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial , 2014, The Lancet.

[61]  Harlan M Krumholz,et al.  National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. , 2014, JAMA internal medicine.

[62]  Bruce W Bode,et al.  Consensus Statement by the American Association of Clinical Endocrinologists/American College of Endocrinology insulin pump management task force. , 2014, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[63]  M. McGuire,et al.  Risk Management and Healthcare Policy Dovepress Adherence and Health Care Costs , 2022 .

[64]  J. Lachin,et al.  Impact of C-Peptide Preservation on Metabolic and Clinical Outcomes in the Diabetes Control and Complications Trial , 2014, Diabetes.

[65]  D. Klonoff,et al.  Threshold-based insulin-pump interruption for reduction of hypoglycemia. , 2013, The New England journal of medicine.

[66]  Kyoung-Bok Min,et al.  Serum C-peptide levels and risk of death among adults without diabetes mellitus , 2013, Canadian Medical Association Journal.

[67]  I. Conget,et al.  Comment on: Greenbaum et al. Fall in C-Peptide During First 2 Years From Diagnosis: Evidence of at Least Two Distinct Phases From Composite Type 1 Diabetes TrialNet Data. Diabetes 2012;61:2066–2073 , 2013, Diabetes.

[68]  R. Vigersky,et al.  Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society , 2013, Diabetes Care.

[69]  Simon R. Heller,et al.  Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. , 2013, The Journal of clinical endocrinology and metabolism.

[70]  Zhao Li,et al.  Impact of Admission Glycemic Variability, Glucose, and Glycosylated Hemoglobin on Major Adverse Cardiac Events After Acute Myocardial Infarction , 2013, Diabetes Care.

[71]  Tracey H. Taveira,et al.  Fasting Serum C‐Peptide Levels Predict Cardiovascular and Overall Death in Nondiabetic Adults , 2012, Journal of the American Heart Association.

[72]  Yongming Qu,et al.  Rate of hypoglycemia in insulin-treated patients with type 2 diabetes can be predicted from glycemic variability data. , 2012, Diabetes technology & therapeutics.

[73]  B. Olsen,et al.  The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial , 2012, Diabetologia.

[74]  C. Beam,et al.  Fall in C-Peptide During First 2 Years From Diagnosis , 2012, Diabetes.

[75]  M. Peyrot,et al.  Insulin adherence behaviours and barriers in the multinational Global Attitudes of Patients and Physicians in Insulin Therapy study , 2012, Diabetic medicine : a journal of the British Diabetic Association.

[76]  Michael E. Miller,et al.  Poor Cognitive Function and Risk of Severe Hypoglycemia in Type 2 Diabetes , 2012, Diabetes Care.

[77]  D. Faustman,et al.  Persistence of Prolonged C-peptide Production in Type 1 Diabetes as Measured With an Ultrasensitive C-peptide Assay , 2012, Diabetes Care.

[78]  R. Slover,et al.  Effectiveness of sensor‐augmented pump therapy in children and adolescents with type 1 diabetes in the STAR 3 study , 2012, Pediatric diabetes.

[79]  Medha N Munshi,et al.  Frequent hypoglycemia among elderly patients with poor glycemic control. , 2011, Archives of internal medicine.

[80]  A. Vargas,et al.  The Relationship of Insulin Secretion and GAD65 Antibody Levels at Diagnosis on Glycemic Control in Type 2 Diabetes , 2010, Journal of pediatric endocrinology & metabolism : JPEM.

[81]  Jennifer K. Sun,et al.  Residual Insulin Production and Pancreatic β-Cell Turnover After 50 Years of Diabetes: Joslin Medalist Study , 2010, Diabetes.

[82]  T. Bailey,et al.  Insulin pump therapy in patients with type 2 diabetes safely improved glycemic control using a simple insulin dosing regimen. , 2010, Diabetes technology & therapeutics.

[83]  A. Vazeou,et al.  Improved Glycemic Control through Continuous Glucose Sensor-Augmented Insulin Pump Therapy: Prospective Results from a Community and Academic Practice Patient Registry , 2009, Journal of diabetes science and technology.

[84]  M. Hallschmid,et al.  Hypoglycemia Unawareness in Older Compared With Middle-Aged Patients With Type 2 Diabetes , 2009, Diabetes Care.

[85]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[86]  M. Fisher,et al.  Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) , 2007 .

[87]  S. Boutreux,et al.  Effectiveness of Intensive Insulin Therapy by Multiple Daily Injections and Continuous Subcutaneous Infusion: A Comparison Study in Type 2 Diabetes with Conventional Insulin Regimen Failure , 2007, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[88]  I. Harman-boehm,et al.  Insulin pump therapy vs. multiple daily injections in obese Type 2 diabetic patients , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[89]  R. Verbrugge,et al.  Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost , 2005, Medical care.

[90]  S. Mudaliar,et al.  Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study. , 2003, Diabetes care.

[91]  Uk-Prospective-Diabetes-Study-Group.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) , 1998, The Lancet.

[92]  E. Chantelau,et al.  Effect of patient-selected intensive insulin therapy on quality of life. , 1997, Patient education and counseling.

[93]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[94]  J. Talbot,et al.  Randomized Trial Comparing Continuous Subcutaneous Insulin Infusion and Conventional Insulin Therapy in Type II Diabetic Patients Poorly Controlled With Sulfonylureas , 1991, Diabetes Care.

[95]  P. Hamet,et al.  Effects of Continuous Subcutaneous Insulin Infusion Versus Multiple Injections on Insulin Receptors in Insulin-Dependent Diabetics , 1987, Diabetes Care.

[96]  Protocol for Diabetes Control and Complications Trial (DCCT) , 1982, Diabetes Care.

[97]  S. Amiel,et al.  Efficacy of insulin pump therapy in elderly patients. , 2015, Diabetes technology & therapeutics.

[98]  Suiying Huang,et al.  Reductions in A1C with pump therapy in type 2 diabetes are independent of C-peptide and anti-glutamic acid decarboxylase antibody concentrations. , 2014, Diabetes technology & therapeutics.

[99]  Mulugeta Gebregziabher,et al.  Longitudinal effects on costs and potential cost savings from improvement , 2012 .

[100]  C. Asche,et al.  A review of diabetes treatment adherence and the association with clinical and economic outcomes. , 2011, Clinical therapeutics.